Compare DCBO & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | EOLS |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.8M | 454.4M |
| IPO Year | 2020 | 2018 |
| Metric | DCBO | EOLS |
|---|---|---|
| Price | $19.37 | $5.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $32.00 | $15.50 |
| AVG Volume (30 Days) | 74.4K | ★ 770.3K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $12.89 | $13.27 |
| Revenue Next Year | $11.44 | $17.62 |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $14.39 | $3.86 |
| 52 Week High | $33.42 | $9.58 |
| Indicator | DCBO | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 42.21 |
| Support Level | $16.37 | $5.99 |
| Resistance Level | $19.66 | $7.16 |
| Average True Range (ATR) | 0.84 | 0.35 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 59.94 | 30.73 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.